Cargando…

Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers

Sustained-release preparation is a hot spot in antitumor drug research, where the first task is to select suitable drug carriers. Research has revealed that carboxylic acid iron metal–organic frameworks (MOFs), constructed from iron (Fe) ions and terephthalic acid, are nontoxic and biocompatible. Du...

Descripción completa

Detalles Bibliográficos
Autores principales: Leng, Xin, Dong, Xiaoxv, Wang, Wenping, Sai, Na, Yang, Chunjing, You, Longtai, Huang, Hongliang, Yin, Xingbin, Ni, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222375/
https://www.ncbi.nlm.nih.gov/pubmed/30274195
http://dx.doi.org/10.3390/molecules23102490
_version_ 1783369192308736000
author Leng, Xin
Dong, Xiaoxv
Wang, Wenping
Sai, Na
Yang, Chunjing
You, Longtai
Huang, Hongliang
Yin, Xingbin
Ni, Jian
author_facet Leng, Xin
Dong, Xiaoxv
Wang, Wenping
Sai, Na
Yang, Chunjing
You, Longtai
Huang, Hongliang
Yin, Xingbin
Ni, Jian
author_sort Leng, Xin
collection PubMed
description Sustained-release preparation is a hot spot in antitumor drug research, where the first task is to select suitable drug carriers. Research has revealed that carboxylic acid iron metal–organic frameworks (MOFs), constructed from iron (Fe) ions and terephthalic acid, are nontoxic and biocompatible. Due to the breathing effect, the skeleton of this mesoporous material is flexible and can reversibly adapt its pore size through drug adsorption. Therefore, we chose one kind of Fe-MOF, MIL-53(Fe), as a carrier for the anticancer drug oridonin (Ori). In this work, we report the design and synthesis of MIL-53(Fe) and explore its ability as a transport vehicle to deliver Ori. MIL-53(Fe) is characterized by scanning electron microscopy and X-ray powder diffraction. A loading capacity of 56.25 wt % was measured by high performance liquid chromatography. This carrier was safe and nontoxic (cell viability > 95.27%), depending on the results of 3-(4,5-dimethylthiazol-2-yl)--2,5-diphenyltetrazolium bromide assays, lactate dehydrogenase assays, and Annexin V-fluoresce isothiocyanate/propidium iodide double-staining assays. After loading the drug, the structure of the MIL-53(Fe) was not destroyed, and Ori was amorphous in MIL-53(Fe). Based on an analysis of the Ori release profile, results suggest that it lasts for more than seven days in vitro. The cumulative release rate of Ori at the seventh day was about 82.23% and 91.75% in phosphate buffer saline solution at 37 °C under pH 7.2 and pH 5.5, respectively. HepG2 cells were chosen to study the cytotoxicity of Ori@MIL-53(Fe), and the results show that the anticancer ratio of Ori@MIL-53(Fe) system reaches 90.62%. Thus, MIL-53 can be used as a carrier for anticancer drugs and Ori@MIL-53(Fe) is a promising sustained-release drug delivery system for the cancer therapy.
format Online
Article
Text
id pubmed-6222375
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62223752018-11-13 Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers Leng, Xin Dong, Xiaoxv Wang, Wenping Sai, Na Yang, Chunjing You, Longtai Huang, Hongliang Yin, Xingbin Ni, Jian Molecules Article Sustained-release preparation is a hot spot in antitumor drug research, where the first task is to select suitable drug carriers. Research has revealed that carboxylic acid iron metal–organic frameworks (MOFs), constructed from iron (Fe) ions and terephthalic acid, are nontoxic and biocompatible. Due to the breathing effect, the skeleton of this mesoporous material is flexible and can reversibly adapt its pore size through drug adsorption. Therefore, we chose one kind of Fe-MOF, MIL-53(Fe), as a carrier for the anticancer drug oridonin (Ori). In this work, we report the design and synthesis of MIL-53(Fe) and explore its ability as a transport vehicle to deliver Ori. MIL-53(Fe) is characterized by scanning electron microscopy and X-ray powder diffraction. A loading capacity of 56.25 wt % was measured by high performance liquid chromatography. This carrier was safe and nontoxic (cell viability > 95.27%), depending on the results of 3-(4,5-dimethylthiazol-2-yl)--2,5-diphenyltetrazolium bromide assays, lactate dehydrogenase assays, and Annexin V-fluoresce isothiocyanate/propidium iodide double-staining assays. After loading the drug, the structure of the MIL-53(Fe) was not destroyed, and Ori was amorphous in MIL-53(Fe). Based on an analysis of the Ori release profile, results suggest that it lasts for more than seven days in vitro. The cumulative release rate of Ori at the seventh day was about 82.23% and 91.75% in phosphate buffer saline solution at 37 °C under pH 7.2 and pH 5.5, respectively. HepG2 cells were chosen to study the cytotoxicity of Ori@MIL-53(Fe), and the results show that the anticancer ratio of Ori@MIL-53(Fe) system reaches 90.62%. Thus, MIL-53 can be used as a carrier for anticancer drugs and Ori@MIL-53(Fe) is a promising sustained-release drug delivery system for the cancer therapy. MDPI 2018-09-28 /pmc/articles/PMC6222375/ /pubmed/30274195 http://dx.doi.org/10.3390/molecules23102490 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Leng, Xin
Dong, Xiaoxv
Wang, Wenping
Sai, Na
Yang, Chunjing
You, Longtai
Huang, Hongliang
Yin, Xingbin
Ni, Jian
Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers
title Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers
title_full Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers
title_fullStr Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers
title_full_unstemmed Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers
title_short Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers
title_sort biocompatible fe-based micropore metal-organic frameworks as sustained-release anticancer drug carriers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222375/
https://www.ncbi.nlm.nih.gov/pubmed/30274195
http://dx.doi.org/10.3390/molecules23102490
work_keys_str_mv AT lengxin biocompatiblefebasedmicroporemetalorganicframeworksassustainedreleaseanticancerdrugcarriers
AT dongxiaoxv biocompatiblefebasedmicroporemetalorganicframeworksassustainedreleaseanticancerdrugcarriers
AT wangwenping biocompatiblefebasedmicroporemetalorganicframeworksassustainedreleaseanticancerdrugcarriers
AT saina biocompatiblefebasedmicroporemetalorganicframeworksassustainedreleaseanticancerdrugcarriers
AT yangchunjing biocompatiblefebasedmicroporemetalorganicframeworksassustainedreleaseanticancerdrugcarriers
AT youlongtai biocompatiblefebasedmicroporemetalorganicframeworksassustainedreleaseanticancerdrugcarriers
AT huanghongliang biocompatiblefebasedmicroporemetalorganicframeworksassustainedreleaseanticancerdrugcarriers
AT yinxingbin biocompatiblefebasedmicroporemetalorganicframeworksassustainedreleaseanticancerdrugcarriers
AT nijian biocompatiblefebasedmicroporemetalorganicframeworksassustainedreleaseanticancerdrugcarriers